Comparison between insulin tolerance test, growth hormone (GH)-releasing hormone (GHRH), GHRH plus acipimox and GHRH plus GH-releasing peptide-6 for the diagnosis of adult GH deficiency in normal subjects, obese and hypopituitary patients.

Cordido F, Alvarez-Castro P, Isidro ML, Casanueva FF, Dieguez C

European journal of endocrinology1 Aug 2003Cited by 44 (Europe PMC)

PMID12887288DOI10.1530/eje.0.1490117PepBankPUB-12887288

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking GHRP-6.

01HumanNot a test of GHRP-6 aloneNon-randomized trialEfficacy outcome
In obese subjects, combined GHRH and GHRP‑6 induced a mean peak GH of 38.5 microg/l, higher than in hypopituitary patients.
In plain wordsIn obese people, GHRH plus GHRP‑6 raised growth hormone much more than in people with pituitary disease.
Peptide
GHRP-6
Outcome
Not applicablePeak GH after GHRH+GHRP-6 in obese subjects
Study
n = 10
Comparator
Hypopituitary patients
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Measurements
Mean peak GH
38.5 microg/l
obese
Source sentences
Summary
GHRH+GHRP-6 induced mean peak GH secretion of 4.1+/-0.9 microg/l for hypopituitary, 38.5+/-6.5 microg/l (P<0.05 vs hypopituitary) for obese and 68.1+/-5.5 microg/l (P<0.05 vs hypopituitary) for normal subjects.
1 context sentence(design, population, supporting numbers)
Summary · context
ten obese normal patients (five female, five male) aged 38-62 Years
In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.
Report a problemFND-1288728802
02HumanNot a test of GHRP-6 aloneNon-randomized trialEfficacy outcome
In normal subjects, combined GHRH and GHRP‑6 induced a mean peak GH of 68.1 microg/l, higher than in hypopituitary patients.
In plain wordsIn healthy people, GHRH plus GHRP‑6 raised growth hormone much more than in people with pituitary disease.
Peptide
GHRP-6
Outcome
Not applicablePeak GH after GHRH+GHRP-6 in normal subjects
Study
n = 10
Comparator
Hypopituitary patients
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Measurements
Mean peak GH
68.1 microg/l
normal
Source sentences
Summary
GHRH+GHRP-6 induced mean peak GH secretion of 4.1+/-0.9 microg/l for hypopituitary, 38.5+/-6.5 microg/l (P<0.05 vs hypopituitary) for obese and 68.1+/-5.5 microg/l (P<0.05 vs hypopituitary) for normal subjects.
1 context sentence(design, population, supporting numbers)
Summary · context
ten normal subjects (five female, five male) aged 33-62 Years
In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.
Report a problemFND-1288728803
03HumanNot a test of GHRP-6 aloneNon-randomized trialEfficacy outcome
In adults with hypopituitarism, combined GHRH and GHRP‑6 induced a mean peak GH of 4.1 microg/l.
In plain wordsIn adults with pituitary disease, GHRH plus GHRP‑6 raised growth hormone only to a low peak.
Peptide
GHRP-6
Outcome
Not applicablePeak GH after GHRH+GHRP-6 in hypopituitary patients
Study
n = 8
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Measurements
Mean peak GH
4.1 microg/l
hypopituitary
Source sentences
Summary
GHRH+GHRP-6 induced mean peak GH secretion of 4.1+/-0.9 microg/l for hypopituitary, 38.5+/-6.5 microg/l (P<0.05 vs hypopituitary) for obese and 68.1+/-5.5 microg/l (P<0.05 vs hypopituitary) for normal subjects.
1 context sentence(design, population, supporting numbers)
Summary · context
Eight adults with hypopituitarism (four female, four male) aged 41-62 Years
In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.
Report a problemFND-1288728801
04HumanNot a test of GHRP-6 aloneNon-randomized trialEfficacy outcome
After combined GHRH and GHRP‑6, the maximal GH response in hypopituitary patients was lower than the minimal response in both normal and obese subjects.
In plain wordsAfter GHRH plus GHRP‑6, the best response in people with pituitary disease was below the lowest response in healthy and obese people.
Peptide
GHRP-6
Outcome
Not applicableSeparation of hypopituitary patients from normal and obese subjects
Study
n: not reported in source
Comparator
Normal and obese subjects
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Source sentences
Summary
In contrast, after GHRH+GHRP-6 the maximal response in hypopituitary patients was lower than the minimal response in normal and obese subjects.
1 context sentence(design, population, supporting numbers)
Summary · context
The aim of the present study was to evaluate the diagnostic capability of four different stimuli of GH secretion: ITT, GHRH, GHRH plus acipimox (GHRH+Ac), and GHRH plus GHRP-6 (GHRH+GHRP-6), in two pathophysiological situations: hypopituitarism and obesity, and normal subjects.
In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.
Report a problemFND-1288728804

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:58 UTC
Study results updated
Version 1
9 Oct 2026, 03:13 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.